Moderna, Inc. Increase (Decrease) in Accounts Receivable
Moderna, Inc. (MRNA) reported Increase (Decrease) in Accounts Receivable of -$167.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-07-31
- Moderna, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$53.00M.
- Moderna, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$114.00M.
- Moderna, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$859.00M.
- Moderna, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $1.01B, a 27.69% decline year-over-year.
- Moderna, Inc. increase (decrease) in accounts receivable for fiscal 2025 was -$156.00M.
- Moderna, Inc. increase (decrease) in accounts receivable for fiscal 2024 was -$534.00M.
- Moderna, Inc. increase (decrease) in accounts receivable for fiscal 2023 was -$493.00M.
- Moderna, Inc. increase (decrease) in accounts receivable for fiscal 2022 was -$1.79B, a 200.34% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 3 month as first filed | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 6 month as first filed | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 9 month as first filed | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$53.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | -$167.00M 10-Q · filed 2026-07-31 | -$1.03B derived: sum of 3 quarters · filed 2026-07-31 | -$13.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | -$114.00M 10-Q · filed 2026-05-01 | -$973.00M derived: sum of 2 quarters · filed 2026-05-01 | $40.00M derived: sum of 3 quarters · filed 2026-05-01 | $10.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-12-31 | -$859.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $154.00M derived: sum of 2 quarters · filed 2026-02-20 | $124.00M derived: sum of 3 quarters · filed 2026-07-31 | -$156.00M 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | $1.01B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $983.00M derived: sum of 2 quarters · filed 2026-07-31 | $703.00M 10-Q · filed 2025-11-06 | -$503.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-06-30 | -$30.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | -$310.00M 10-Q · filed 2026-07-31 | -$1.52B derived: sum of 3 quarters · filed 2026-07-31 | -$115.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-03-31 | -$280.00M 10-Q · filed 2026-05-01 | -$1.49B derived: sum of 2 quarters · filed 2026-05-01 | -$85.00M derived: sum of 3 quarters · filed 2026-05-01 | -$59.00M derived: sum of 4 quarters · filed 2026-05-01 | ||||
| 2024-12-31 | -$1.21B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $195.00M derived: sum of 2 quarters · filed 2026-02-20 | $221.00M derived: sum of 3 quarters · filed 2026-02-20 | -$534.00M 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | $1.40B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.43B derived: sum of 2 quarters · filed 2025-11-06 | $672.00M 10-Q · filed 2025-11-06 | -$302.00M derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | $26.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | -$729.00M 10-Q · filed 2025-08-01 | -$1.70B derived: sum of 3 quarters · filed 2026-02-20 | -$69.00M derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | -$755.00M 10-Q · filed 2025-05-01 | -$1.73B derived: sum of 2 quarters · filed 2026-02-20 | -$95.00M derived: sum of 3 quarters · filed 2026-02-20 | -$976.00M derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | -$974.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $660.00M derived: sum of 2 quarters · filed 2026-02-20 | -$221.00M derived: sum of 3 quarters · filed 2026-02-20 | -$493.00M 10-K · filed 2026-02-20 | ||||
| 2023-09-30 | $1.63B derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $753.00M derived: sum of 2 quarters · filed 2024-11-07 | $481.00M 10-Q · filed 2024-11-07 | -$829.00M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-06-30 | -$881.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$1.15B 10-Q · filed 2024-08-01 | -$2.46B derived: sum of 3 quarters · filed 2025-02-21 | -$2.46B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-03-31 | -$272.00M 10-Q · filed 2024-05-02 | -$1.58B derived: sum of 2 quarters · filed 2025-02-21 | -$1.58B derived: sum of 3 quarters · filed 2025-02-21 | -$2.06B derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2022-12-31 | -$1.31B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$1.31B derived: sum of 2 quarters · filed 2025-02-21 | -$1.79B derived: sum of 3 quarters · filed 2025-02-21 | -$1.79B 10-K · filed 2025-02-21 | ||||
| 2022-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$479.00M derived: sum of 2 quarters · filed 2023-11-03 | -$480.00M 10-Q · filed 2023-11-03 | -$447.00M derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-06-30 | -$483.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$484.00M 10-Q · filed 2023-08-03 | -$451.00M derived: sum of 3 quarters · filed 2024-02-23 | $671.00M derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-03-31 | -$1.00M 10-Q · filed 2023-05-04 | $32.00M derived: sum of 2 quarters · filed 2024-02-23 | $1.15B derived: sum of 3 quarters · filed 2024-02-23 | -$36.00M derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2021-12-31 | $33.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $1.16B derived: sum of 2 quarters · filed 2024-02-23 | -$35.00M derived: sum of 3 quarters · filed 2024-02-23 | $1.78B 10-K · filed 2024-02-23 | ||||
| 2021-09-30 | $1.12B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$68.00M derived: sum of 2 quarters · filed 2022-11-03 | $1.75B 10-Q · filed 2022-11-03 | $2.95B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-06-30 | -$1.19B derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $629.00M 10-Q · filed 2022-08-03 | $1.83B derived: sum of 3 quarters · filed 2023-02-24 | $1.99B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-03-31 | $1.82B 10-Q · filed 2022-05-04 | $3.02B derived: sum of 2 quarters · filed 2023-02-24 | $3.18B derived: sum of 3 quarters · filed 2023-02-24 | $3.20B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2020-12-31 | $1.20B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $1.36B derived: sum of 2 quarters · filed 2023-02-24 | $1.38B derived: sum of 3 quarters · filed 2023-02-24 | $1.39B 10-K · filed 2023-02-24 | $1.39B 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $157.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $183.00M derived: sum of 2 quarters · filed 2021-11-04 | $185.00M 10-Q · filed 2021-11-04 | $185.13M 10-Q · filed 2020-10-30 | $182.37M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-06-30 | $26.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $28.00M 10-Q · filed 2021-08-05 | $27.99M 10-Q · filed 2020-08-06 | $25.37M derived: sum of 3 quarters · filed 2022-02-25 | $29.07M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-03-31 | $2.00M 10-Q · filed 2021-05-06 | $585.00K 10-Q · filed 2020-05-07 | -$631.00K derived: sum of 2 quarters · filed 2022-02-25 | $3.07M derived: sum of 3 quarters · filed 2022-02-25 | $1.04M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2019-12-31 | -$2.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $1.07M derived: sum of 2 quarters · filed 2022-02-25 | -$960.00K derived: sum of 3 quarters · filed 2022-02-25 | -$7.00M 10-K · filed 2022-02-25 | -$6.65M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $3.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $1.67M derived: sum of 2 quarters · filed 2020-10-30 | -$4.37M 10-Q · filed 2020-10-30 | -$8.89M 10-Q · filed 2019-11-06 | -$3.17M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2019-06-30 | -$2.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$8.07M 10-Q · filed 2020-08-06 | -$8.19M 10-Q · filed 2019-08-08 | -$6.86M derived: sum of 3 quarters · filed 2021-02-26 | -$8.41M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2019-03-31 | -$6.04M 10-Q · filed 2020-05-07 | -$4.84M derived: sum of 2 quarters · filed 2021-02-26 | -$6.38M derived: sum of 3 quarters · filed 2021-02-26 | -$3.00M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2018-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$343.00K derived: sum of 2 quarters · filed 2021-02-26 | $3.04M derived: sum of 3 quarters · filed 2021-02-26 | -$832.00K 10-K · filed 2021-02-26 | -$195.00K 10-K · filed 2019-03-13 | |||
| 2018-09-30 | -$1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $1.84M derived: sum of 2 quarters · filed 2019-11-06 | -$2.04M 10-Q · filed 2019-11-06 | |||||
| 2018-06-30 | $3.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$489.00K 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | -$3.88M 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | -$1.48M 10-K · filed 2020-02-27 | |||||||
| 2016-12-31 | $8.64M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |